Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06937905 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Study acronym: TARLANEC
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 1, 2025 to Feb 6, 2026 · Primary completion date: Sep 1, 2028 to Feb 1, 2029 · Completion date: Mar 1, 2030 to Aug 1, 2030 · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Sep 1, 2025 to Feb 6, 2026
    • Primary completion date: Sep 1, 2028 to Feb 1, 2029
    • Completion date: Mar 1, 2030 to Aug 1, 2030
    • Site details revised at 40 of 40 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Trial Details
NCT Number NCT06937905
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Neuroendocrine Carcinoma
Enrollment 129 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov